Post Menopausal Osteoporosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major post menopausal osteoporosis markets reached a value of US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.0 Billion by 2034, exhibiting a growth rate (CAGR) of 3.8% during 2024-2034.
The post-menopausal osteoporosis market has been comprehensively analyzed in IMARC's new report titled "Post Menopausal Osteoporosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post menopausal osteoporosis is a type of osteoporosis that develops in women after menopause. Osteoporosis is a condition characterized by low bone density and structural deterioration of bone tissue, leading to increased fragility as well as a higher risk of fractures. Post menopausal osteoporosis often does not cause noticeable symptoms until a fracture occurs. However, some common indications may be present, including back pain, loss of height over time, a stooped posture (kyphosis), greater susceptibility to fractures, particularly in the wrist, hip, and spine, etc. In many cases, fractures can occur with minimal trauma or even during routine daily activities. The diagnosis of post menopausal osteoporosis typically involves a combination of clinical assessment and diagnostic tests. Healthcare professionals evaluate the patient's medical history, risk factors, and symptoms to determine the likelihood of osteoporosis. Dual-energy X-ray absorptiometry (DXA) is the most commonly used test to measure bone mineral density (BMD) and diagnose osteoporosis. Numerous additional procedures, such as laboratory blood tests and vertebral imaging, may be done to rule out other causes and assess fracture risk.
The escalating cases of decline in estrogen levels during menopause that result in an imbalance between bone formation and bone resorption, thereby leading to a net loss of bone density, are primarily driving the post menopausal osteoporosis market. Furthermore, the rising incidence of several associated risk factors, including genetic predisposition, inadequate intake of calcium and vitamin D, lack of physical activity, prolonged use of corticosteroids, excessive alcohol consumption, etc., is also bolstering market growth. In addition to this, the widespread adoption of oral bisphosphonates, such as alendronate and risedronate, to inhibit bone resorption and reduce the likelihood of fractures in patients is creating a positive outlook for the market. Moreover, the rising utilization of novel sequential therapies involving the use of anabolic agents like teriparatide followed by antiresorptive medications for optimizing bone formation and reducing bone loss is acting as another significant growth-inducing factor. Additionally, the emerging popularity of the trabecular bone score (TBS) imaging technique, since it assesses the microarchitecture of trabecular bone and provides additional information about bone quality, fracture risk, and treatment response, is expected to drive the post menopausal osteoporosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the post-menopausal osteoporosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post menopausal osteoporosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post menopausal osteoporosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the post menopausal osteoporosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the post menopausal osteoporosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current post menopausal osteoporosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the post menopausal osteoporosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the post menopausal osteoporosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the post menopausal osteoporosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of post menopausal osteoporosis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of post menopausal osteoporosis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of post menopausal osteoporosis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with post menopausal osteoporosis across the seven major markets?
What is the size of the post menopausal osteoporosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of post menopausal osteoporosis?
What will be the growth rate of patients across the seven major markets?
Post Menopausal Osteoporosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for post menopausal osteoporosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post menopausal osteoporosis market?
What are the key regulatory events related to the post menopausal osteoporosis market?
What is the structure of clinical trial landscape by status related to the post menopausal osteoporosis market?
What is the structure of clinical trial landscape by phase related to the post menopausal osteoporosis market?
What is the structure of clinical trial landscape by route of administration related to the post menopausal osteoporosis market?
The post-menopausal osteoporosis market has been comprehensively analyzed in IMARC's new report titled "Post Menopausal Osteoporosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post menopausal osteoporosis is a type of osteoporosis that develops in women after menopause. Osteoporosis is a condition characterized by low bone density and structural deterioration of bone tissue, leading to increased fragility as well as a higher risk of fractures. Post menopausal osteoporosis often does not cause noticeable symptoms until a fracture occurs. However, some common indications may be present, including back pain, loss of height over time, a stooped posture (kyphosis), greater susceptibility to fractures, particularly in the wrist, hip, and spine, etc. In many cases, fractures can occur with minimal trauma or even during routine daily activities. The diagnosis of post menopausal osteoporosis typically involves a combination of clinical assessment and diagnostic tests. Healthcare professionals evaluate the patient's medical history, risk factors, and symptoms to determine the likelihood of osteoporosis. Dual-energy X-ray absorptiometry (DXA) is the most commonly used test to measure bone mineral density (BMD) and diagnose osteoporosis. Numerous additional procedures, such as laboratory blood tests and vertebral imaging, may be done to rule out other causes and assess fracture risk.
The escalating cases of decline in estrogen levels during menopause that result in an imbalance between bone formation and bone resorption, thereby leading to a net loss of bone density, are primarily driving the post menopausal osteoporosis market. Furthermore, the rising incidence of several associated risk factors, including genetic predisposition, inadequate intake of calcium and vitamin D, lack of physical activity, prolonged use of corticosteroids, excessive alcohol consumption, etc., is also bolstering market growth. In addition to this, the widespread adoption of oral bisphosphonates, such as alendronate and risedronate, to inhibit bone resorption and reduce the likelihood of fractures in patients is creating a positive outlook for the market. Moreover, the rising utilization of novel sequential therapies involving the use of anabolic agents like teriparatide followed by antiresorptive medications for optimizing bone formation and reducing bone loss is acting as another significant growth-inducing factor. Additionally, the emerging popularity of the trabecular bone score (TBS) imaging technique, since it assesses the microarchitecture of trabecular bone and provides additional information about bone quality, fracture risk, and treatment response, is expected to drive the post menopausal osteoporosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the post-menopausal osteoporosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post menopausal osteoporosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post menopausal osteoporosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the post menopausal osteoporosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the post menopausal osteoporosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current post menopausal osteoporosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the post menopausal osteoporosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the post menopausal osteoporosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the post menopausal osteoporosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of post menopausal osteoporosis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of post menopausal osteoporosis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of post menopausal osteoporosis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with post menopausal osteoporosis across the seven major markets?
What is the size of the post menopausal osteoporosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of post menopausal osteoporosis?
What will be the growth rate of patients across the seven major markets?
Post Menopausal Osteoporosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for post menopausal osteoporosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post menopausal osteoporosis market?
What are the key regulatory events related to the post menopausal osteoporosis market?
What is the structure of clinical trial landscape by status related to the post menopausal osteoporosis market?
What is the structure of clinical trial landscape by phase related to the post menopausal osteoporosis market?
What is the structure of clinical trial landscape by route of administration related to the post menopausal osteoporosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POST MENOPAUSAL OSTEOPOROSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POST MENOPAUSAL OSTEOPOROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POST MENOPAUSAL OSTEOPOROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 POST MENOPAUSAL OSTEOPOROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POST MENOPAUSAL OSTEOPOROSIS - UNMET NEEDS
10 POST MENOPAUSAL OSTEOPOROSIS - KEY ENDPOINTS OF TREATMENT
11 POST MENOPAUSAL OSTEOPOROSIS - MARKETED PRODUCTS
11.1 List of Post Menopausal Osteoporosis Marketed Drugs Across the Top 7 Markets
11.1.1 Evenity (Romosozumab) - Amgen/UCB
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Alora (Estradiol transdermal) - AbbVie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Boniva (Ibandronic acid) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Prolia (Denosumab) - Amgen
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Reclast (Zoledronic acid) - Novartis
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POST MENOPAUSAL OSTEOPOROSIS - PIPELINE DRUGS
12.1 List of Post Menopausal Osteoporosis Pipeline Drugs Across the Top 7 Markets
12.1.1 RGB 14 P - Gedeon Richter
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TVB-009P - Teva Pharmaceutical
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 FKS518 - Fresenius Kabi
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 LY2541546 - Eli Lilly
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SB 16 - Samsung Bioepis
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POST MENOPAUSAL OSTEOPOROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POST MENOPAUSAL OSTEOPOROSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POST MENOPAUSAL OSTEOPOROSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Post Menopausal Osteoporosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Post Menopausal Osteoporosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Post Menopausal Osteoporosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Post Menopausal Osteoporosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Post Menopausal Osteoporosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Post Menopausal Osteoporosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Post Menopausal Osteoporosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Post Menopausal Osteoporosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
16 POST MENOPAUSAL OSTEOPOROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POST MENOPAUSAL OSTEOPOROSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POST MENOPAUSAL OSTEOPOROSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POST MENOPAUSAL OSTEOPOROSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POST MENOPAUSAL OSTEOPOROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POST MENOPAUSAL OSTEOPOROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 POST MENOPAUSAL OSTEOPOROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POST MENOPAUSAL OSTEOPOROSIS - UNMET NEEDS
10 POST MENOPAUSAL OSTEOPOROSIS - KEY ENDPOINTS OF TREATMENT
11 POST MENOPAUSAL OSTEOPOROSIS - MARKETED PRODUCTS
11.1 List of Post Menopausal Osteoporosis Marketed Drugs Across the Top 7 Markets
11.1.1 Evenity (Romosozumab) - Amgen/UCB
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Alora (Estradiol transdermal) - AbbVie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Boniva (Ibandronic acid) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Prolia (Denosumab) - Amgen
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Reclast (Zoledronic acid) - Novartis
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POST MENOPAUSAL OSTEOPOROSIS - PIPELINE DRUGS
12.1 List of Post Menopausal Osteoporosis Pipeline Drugs Across the Top 7 Markets
12.1.1 RGB 14 P - Gedeon Richter
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TVB-009P - Teva Pharmaceutical
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 FKS518 - Fresenius Kabi
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 LY2541546 - Eli Lilly
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SB 16 - Samsung Bioepis
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POST MENOPAUSAL OSTEOPOROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POST MENOPAUSAL OSTEOPOROSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POST MENOPAUSAL OSTEOPOROSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Post Menopausal Osteoporosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Post Menopausal Osteoporosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Post Menopausal Osteoporosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Post Menopausal Osteoporosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Post Menopausal Osteoporosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Post Menopausal Osteoporosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Post Menopausal Osteoporosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Post Menopausal Osteoporosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Post Menopausal Osteoporosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Post Menopausal Osteoporosis - Access and Reimbursement Overview
16 POST MENOPAUSAL OSTEOPOROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POST MENOPAUSAL OSTEOPOROSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POST MENOPAUSAL OSTEOPOROSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
